Linda joined the BioPharma industry in 1983 and has spent the last 30+ years in regulatory strategy, policy, and intelligence roles at Pfizer (Seagen acquisition), Sanofi, Bayer, and GSK (Block Drug acquisition) She has been an Adjunct Professor in the Temple University RAQA graduate program since 1998.
She attained regulatory affairs certification for the US, Canada, and Europe, and was an inductee to the 2011 Class of RAPS Fellows. Linda was honored with the RAPS 2020 Founder’s Award as well as the Drug Information Association's (DIA) 2012 Excellence in Volunteer Leadership, the 2019 Americas Inspire Awards, and the 2022 Global Inspire Award - Community Engagement.
She is a past two-term member of the RAPS Board of Directors, current chair of the RAPS Industry Board, and immediate past chair of of the NJ/NY RAPS Chapter. Linda is past Chair of the DIA Regulatory Affairs Community and founder of the DIA Regulatory Intelligence Working Group.
She was Program Chair for Convergence 2018-2019. She is co-chair of the RAPS Regulatory Intelligence Conference (2024-2026), was on the Planning Committee for the RAPS/TOPRA UK RI Conference (2025) and lead editor of the RAPS 2026 book, "Regulatory Intelligence, Reimagined."
She is most proud of her role as educator and mentor to those entering the regulatory profession.